Another roadblock for DOJ campaign against trans health - Report - MDSpire

Another roadblock for DOJ campaign against trans health

  • By

  • Theresa Gaffney

  • June 25, 2026

  • 0 min

Share

Clinical Report: New Challenge for DOJ's Efforts on Transgender Healthcare

Overview

A federal judge has temporarily blocked efforts by the DOJ to obtain medical records of transgender patients in New York. This ruling is part of ongoing legal actions surrounding gender-affirming care.

Background

Legal and political actions are impacting access to gender-affirming treatments for transgender individuals, particularly minors. Recent federal initiatives have raised concerns about confidentiality and rights.

Data Highlights

No numerical or trial data available in the source material.

Key Findings

  • A federal judge blocked DOJ's request for medical records of transgender patients in New York.
  • The ruling was made by Judge Katherine Polk Failla, who criticized the government's actions.
  • This legal challenge follows similar requests that have been ruled against in various jurisdictions.
  • Many hospitals have ceased providing gender-affirming care to minors since the Trump administration.
  • The DOJ's actions are part of a broader strategy to restrict access to gender-affirming care.

Clinical Implications

Healthcare providers should be aware of the evolving legal landscape surrounding transgender healthcare.

Conclusion

The ruling against the DOJ's subpoenas reflects ongoing legal complexities surrounding transgender healthcare access.

Related Resources & Content

  1. Stat News, 2026 -- Judge temporarily blocks subpoenas in criminal probe of transgender care at New York hospitals
  2. Kaiser Family Foundation (KFF), 2026 -- Texas Emerges as Focus of New Trump Administration Actions to Limit Gender-Affirming Care
  3. Stat News, 2026 -- New subpoena suggests DOJ has begun criminal investigation of gender-affirming care
  4. Stat News, 2026 -- FTC, four state AGs sue transgender health group over care standards
  5. 42 CFR Part 8 Final Rule - Frequently Asked Questions | SAMHSA
  6. Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose: A Review | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network
  7. Substance Use Disorders - Statutes, Regulations, and Guidelines | SAMHSA

Original Source(s)

Related Content